Compare LARK & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | MXCT |
|---|---|---|
| Founded | 1885 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.1M | 155.8M |
| IPO Year | 2001 | 2021 |
| Metric | LARK | MXCT |
|---|---|---|
| Price | $32.30 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.11 |
| AVG Volume (30 Days) | 4.6K | ★ 1.9M |
| Earning Date | 10-28-2026 | 11-10-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ 35.84 | N/A |
| EPS | ★ 2.59 | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | N/A | $10.06 |
| P/E Ratio | $12.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.57 | $0.64 |
| 52 Week High | $34.60 | $1.81 |
| Indicator | LARK | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 54.47 | 43.69 |
| Support Level | $30.92 | $1.07 |
| Resistance Level | $32.40 | $1.27 |
| Average True Range (ATR) | 0.43 | 0.17 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 53.56 | 24.32 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.